1-3 of 3
Marta Cortes-Cros
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract LB222: Elucidating the cellular responses and mechanism of action of 177Lu-based radioligand therapy

Marco Ranzani, Sravanth Hindupur, Alessandro Cicconi, Guillermo Sastre-Moreno, Alexander Kristian, Barbara Schacher Engstler, Benika Pinch, Charlene Hartnagel, Delphine Gorses, Elise Simon, Emeline Mandon, Emilien Schramm, Fanny Schaeffer, Josefine Reber, Louise Barys, Luisa Deberle, Milene Walter, Ralph Bessey, Riccardo Destefani, Xavier Miot, Elias Elinati, Nan Shao, Marie Boursier, Joseph Barlow, Asmita Thapa, Alessandro Galbiati, Diego Grande, Eeson Rajendra, Niall Martin, Graeme Smith, Tobias Schmelzle, Markus Reschke, Helen Robinson, Marta Cortes-Cros
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): LB222.
https://doi.org/10.1158/1538-7445.AM2024-LB222
Published: 05 April 2024
View article titled, Abstract LB222: Elucidating the cellular responses and mechanism of action of <sup>177</sup>Lu-based radioligand therapy
Journal Articles

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201

Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, Jeanette Fuchs, Emilie A. Chapeau, Markus Wartmann, Dario Sterker, Vincent Romanet, Masato Murakami, Grainne Kerr, Eric Y. Durand, Swann Gaulis, Marta Cortes-Cros, Stephan Ruetz, Therese-Marie Stachyra, Joerg Kallen, Pascal Furet, Jens Würthner, Nelson Guerreiro, Ensar Halilovic, Astrid Jullion, Audrey Kauffmann, Emil Kuriakose, Marion Wiesmann, Michael R. Jensen, Francesco Hofmann, William R. Sellers
Journal: Cancer Research
Series: Author Choice
Cancer Res (2018) 78 (21): 6257–6267.
https://doi.org/10.1158/0008-5472.CAN-18-0338
Published: 01 November 2018
View article titled, Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201
Open the PDF for Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201 in another window
Includes: Supplementary data
Journal Articles

Abstract #4766: FGFR genetic alterations or constitutive pathway activation define sensitivity to TKI258, an FGFR kinase inhibitor

Diana Graus Porta, Christelle Stamm, Sandra Mollé, Sabine Zumstein-Mecker, Yao Yao, Giordano Caponigro, Marta Cortés-Cros, Carlos Garcia-Echeverria
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 4766.
Published: 01 May 2009
View article titled, Abstract #4766: FGFR genetic alterations or constitutive pathway activation define sensitivity to TKI258, an FGFR kinase inhibitor